Literature DB >> 96132

Immunogenicity of polysaccharides from type III, group B Streptococcus.

C J Baker, M S Edwards, D L Kasper.   

Abstract

The immunogenicity and safety of two polysaccharides isolated from type III, group B Streptococcus, were tested in adults selected for existing low concentrations of natural antibody to the capsular polysaccharide of this organism. Both vaccine preparations (trichloroacetic acid and EDTA) were found to lack pyrogenicity and toxicity for experimental animals. A single 50-microgram subcutaneous injection of either polysaccharide in human subjects elicited significant increase in antibody concentration in immunized compared with control individuals receiving phosphate-buffered saline. Antibody responses were maximal by 2 wk and remained at 21 wk after immunization. Vaccine-induced antibody was primarily of the IgG class. Of the two vaccines, the larger molecular size polysaccharide was significantly more immunogenic. Although no systemic reactions were recorded, mild transient local reactions occurred in 45% of vaccinees.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 96132      PMCID: PMC372629          DOI: 10.1172/JCI109011

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  11 in total

1.  The effect of variation in molecular weight on the antigenicity of dextran in man.

Authors:  E A KABAT; A E BEZER
Journal:  Arch Biochem Biophys       Date:  1958-12       Impact factor: 4.013

2.  Microcapsule of type III strains of group B Streptococcus: production and morphology.

Authors:  C J Baker; D L Kasper
Journal:  Infect Immun       Date:  1976-01       Impact factor: 3.441

Review 3.  The emergence of group B streptococci in infections of the newborn infant.

Authors:  B F Anthony; D M Okada
Journal:  Annu Rev Med       Date:  1977       Impact factor: 13.739

4.  Antigenic specificity of opsonophagocytic antibodies in rabbit anti-sera to group B streptococci.

Authors:  R S Baltimore; D L Kasper; C J Baker; D K Goroff
Journal:  J Immunol       Date:  1977-02       Impact factor: 5.422

5.  Characterization of gonococcal antigens responsible for induction of bactericidal antibody in disseminated infection.

Authors:  P A Rice; D L Kasper
Journal:  J Clin Invest       Date:  1977-11       Impact factor: 14.808

6.  Cutaneous reactions and antibody response to meningococcal group C polysaccharide vaccines in man.

Authors:  M S Artenstein; R Gold; J G Zimmerly; F A Wyle; W C Branche; C Harkins
Journal:  J Infect Dis       Date:  1970-04       Impact factor: 5.226

7.  Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection.

Authors:  C J Baker; D L Kasper
Journal:  N Engl J Med       Date:  1976-04-01       Impact factor: 91.245

8.  Immunization of humans with polyribophosphate, the capsular antigen of Hemophilus influenzae, type b.

Authors:  P Anderson; G Peter; R B Johnston; L H Wetterlow; D H Smith
Journal:  J Clin Invest       Date:  1972-01       Impact factor: 14.808

9.  Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus.

Authors:  C J Baker; D L Kasper; A Paredes; S Alpert; W M McCormack; D Goroff
Journal:  J Clin Invest       Date:  1977-05       Impact factor: 14.808

10.  Immunochemical characterization of the "native" type III polysaccharide of group B Streptococcus.

Authors:  C J Baker; D L Kasper; C E Davis
Journal:  J Exp Med       Date:  1976-02-01       Impact factor: 14.307

View more
  29 in total

1.  Group B streptococcal infection in the newborn.

Authors:  M I Marks
Journal:  Can Med Assoc J       Date:  1979-10-20       Impact factor: 8.262

2.  Immunoprophylaxis and immunotherapy of neonatal group B streptococcal infections.

Authors:  S P Gotoff
Journal:  Infection       Date:  1985       Impact factor: 3.553

3.  Synthesis and immunological properties of conjugates composed of group B streptococcus type III capsular polysaccharide covalently bound to tetanus toxoid.

Authors:  T Lagergard; J Shiloach; J B Robbins; R Schneerson
Journal:  Infect Immun       Date:  1990-03       Impact factor: 3.441

4.  Immunoprophylaxis and immunotherapy of neonatal group B streptococcal infections.

Authors:  S P Gotoff
Journal:  Infection       Date:  1984 Mar-Apr       Impact factor: 3.553

5.  Infection and defences in neonates.

Authors:  M L Chiswick
Journal:  Br Med J (Clin Res Ed)       Date:  1983-04-30

6.  Enzyme-linked immunosorbent assay for group B streptococcal antibodies.

Authors:  N S Rote; N L Taylor; A O Shigeoka; J R Scott; H R Hill
Journal:  Infect Immun       Date:  1980-01       Impact factor: 3.441

7.  Immunogenicity in animals of a polysaccharide-protein conjugate vaccine against type III group B Streptococcus.

Authors:  M R Wessels; L C Paoletti; D L Kasper; J L DiFabio; F Michon; K Holme; H J Jennings
Journal:  J Clin Invest       Date:  1990-11       Impact factor: 14.808

8.  Immunoglobulin G and M composition of naturally occurring antibody to type III group B streptococci.

Authors:  B F Anthony; N F Concepcion; C A Wass; D C Heiner
Journal:  Infect Immun       Date:  1984-10       Impact factor: 3.441

9.  Class specificity of naturally acquired and vaccine-induced antibody to type III group B streptococcal capsular polysaccharide: determination with a radioimmunoprecipitin assay.

Authors:  M S Edwards; P A Fuselier; M A Rench; D L Kasper; C J Baker
Journal:  Infect Immun       Date:  1984-05       Impact factor: 3.441

10.  Murine monoclonal antibodies to type Ib polysaccharide of group B streptococci bind to human milk oligosaccharides.

Authors:  D G Pritchard; B M Gray; M L Egan
Journal:  Infect Immun       Date:  1992-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.